文献速递脑血管病

静脉输注同种异体间充质干细胞治疗慢性卒中的I/II期安全性及初步疗效研究

Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke.
PubMed 文献 · Stroke · 2019-09-09

该研究评估静脉输注同种异体缺血耐受间充质干细胞在慢性缺血性卒中伴显著功能缺损患者中的安全性和初步疗效。I期剂量递增(0.5、1.0、1.5百万细胞/kg,各n=5)确认安全后,II期扩展队列(n=21)接受1.5百万细胞/kg。36例患者随访1年,治疗安全,所有行为学终点在12个月内显著改善,支持开展随机安慰剂对照研究。

要点

  • 静脉输注同种异体缺血耐受间充质干细胞在慢性卒中患者中安全,严重不良事件均与治疗无关。
  • Barthel指数在输注后6个月平均增加6.8分(P=0.002),12个月增加10.8分(P<0.001)。
  • 达到优良功能结局(Barthel≥95)的比例从基线11.4%升至12个月35.5%。

核心结论

  • 静脉输注同种异体缺血耐受间充质干细胞在慢性卒中伴显著功能缺损患者中安全,并提示行为学改善。
  • 数据支持在该人群中开展随机安慰剂对照研究。

研究设计与样本

  • I/II期研究,纳入缺血性卒中>6个月且NIHSS评分≥6伴显著功能障碍的患者。
  • I期剂量递增设计3个剂量组(0.5、1.0、1.5百万细胞/kg),每组n=5;II期为扩展安全性队列(n=21),接受1.5百万细胞/kg。
  • 共36例受试者,主要终点为1年安全性,次要终点为行为学变化。

主要发现

  • I期各剂量均安全,II期受试者接受1.5百万细胞/kg。
  • 基线平均卒中后4.2±4.6年,年龄61.1±10.8岁,NIHSS评分8(6.5-10),Barthel指数65±29。
  • 15例严重不良事件均与治疗无关;2例轻度不良事件(尿路感染和静脉部位刺激)可能与治疗相关。
  • Barthel指数6个月增加6.8±11.4分(P=0.002),12个月增加10.8±15.5分(P<0.001)。
  • 优良功能结局(Barthel≥95)比例从基线11.4%升至6个月27.3%、12个月35.5%。

关键数值与推荐

  • 入组标准:缺血性卒中>6个月,NIHSS评分≥6,伴显著功能障碍。
  • I期剂量递增:0.5、1.0、1.5百万细胞/kg,各n=5;II期剂量1.5百万细胞/kg。
  • 主要终点:1年安全性;次要终点:行为学变化。

临床怎么用

  • 该疗法在慢性卒中伴显著功能缺损患者中显示安全性和行为学改善信号,但尚需随机对照试验验证。
  • 临床决策时应告知患者目前证据为I/II期初步结果,不作为常规治疗推荐。

局限性

  • 非随机、无安慰剂对照,不能排除安慰剂效应或自然恢复。
  • 样本量小(n=36),II期仅为扩展安全性队列。
  • 2例失访、1例退出、2例死亡(与治疗无关),可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Stroke is a leading cause of long-term disability. Limited treatment options exist for patients with chronic stroke and substantial functional deficits. The current study examined safety and preliminary efficacy estimates of intravenous allogeneic mesenchymal stem cells in this population. Methods- Entry criteria included ischemic stroke >6 months prior and substantial impairment (National Institutes of Health Stroke Scale score ≥6) and disability. Enrollees received a single intravenous dose of allogeneic ischemia-tolerant mesenchymal stem cells. Phase 1 used a dose-escalation design (3 tiers, n=5 each). Phase 2 was an expanded safety cohort. The primary end point was safety over 1-year. Secondary end points examined behavioral change. Results- In phase 1 (n=15), each dose (0.5, 1.0, and 1.5 million cells/kg body weight) was found safe, so phase 2 subjects (n=21) received 1.5 million cells/kg. At baseline, subjects (n=36) averaged 4.2±4.6 years poststroke, age 61.1±10.8 years, National Institutes of Health Stroke Scale score 8 (6.5-10), and Barthel Index 65±29. Two were lost to follow-up, one was withdrawn and 2 died (unrelated to study treatment). Of 15 serious adverse events, none was possibly or probably related to study treatment. Two mild adverse events were possibly related to study treatment, a urinary tract infection and intravenous site irritation. Treatment was safe based on serial exams, electrocardiograms, laboratory tests, and computed tomography scans of chest/abdomen/pelvis. All behavioral end points showed significant gains over the 12-months of follow-up. For example, Barthel Index scores increased by 6.8±11.4 points (mean±SD) at 6-months (P=0.002) and by 10.8±15.5 points at 12-months (P<0.001) post-infusion; the proportion of patients achieving excellent functional outcome (Barthel score ≥95) increased from 11.4% at baseline to 27.3% at 6-months and to 35.5% at 12-months. Conclusions- Intravenous transfusion of allogeneic ischemia-tolerant mesenchymal stem cell in patients with chronic stroke and substantial functional deficits was safe and suggested behavioral gains. These data support proceeding to a randomized, placebo-controlled study of this therapy in this population. Clinical Trial Registration- URL: https://www.clinicaltrials.gov. Unique identifier: NCT01297413.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Levy ML, Crawford JR, Dib N, et al. Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke. Stroke. 2019. PMID: 31495331. doi:10.1161/STROKEAHA.119.026318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。